Recovery and return to profitability at Thepenier
First written in FY2016. 19 of 41 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1AdvancedAnnual report
「In Europe, where the subsidiaries THEPENIER PHARMA & COSMETICS S.A.S. (the “Tepnier Company”) and Nippon Shikizai France S.A.S. (the “Nippon Shikizai France Company”) are located, the economy was on a gradual recovery track during the interim consolidated accounting period (January to June), and orders for pharmaceuticals and cosmetics also showed signs of recovery. Net sales increased in both euro terms and after conversion into yen, rising 34.6% year on year to ¥3,147 million. In terms of earnings, the increase in sales offset the sharp rises in labor costs and other prices, resulting in operating profit of ¥194 thousand (operating loss of ¥83 million in the same period of the previous year).」
The European business turned from an operating loss in the same period of the previous year to operating profit, driven by recovering orders and higher sales. - 2026-10-13AdvancedEarnings
「利益面では、売上高の増収で人件費や諸物価の高騰を打ち返して、194千円の営業利益（前年同期は83百万円の営業損失）となりました。」
欧州事業は増収により、前年同期の営業損失から営業利益へ転じた。 - 2026-10-07Mitigateds.kabutan.jp
「THEPENIER PHARMA & COSMETICS S.A.S. and Nippon Shikizai France S.A.S., our consolidated subsidiaries in France, are expected to exceed their forecasts on a combined basis. Orders for pharmaceuticals and cosmetics have recovered, resulting in higher sales both in euro terms and after conversion into yen, despite higher personnel and other costs.」
The French consolidated subsidiaries recorded higher sales as orders recovered, and their combined performance is now expected to exceed forecasts. - FY2026WorsenedAnnual report
「Orders for both pharmaceuticals and cosmetics remained weak in Europe. Revenue declined both in euro terms and after conversion into yen, falling 4.2% from the previous fiscal year to ¥5,043 million. Profit was affected by the revenue decline and higher personnel and other costs, as well as delays in bringing some new equipment at THEPENIER into operation and weak utilization at Nippon Shikizai France, resulting in an operating loss of ¥82 million, compared with an operating loss of ¥73 million in the previous consolidated fiscal year.」
The European business posted lower revenue, and its operating loss widened from ¥73 million in the previous fiscal year to ¥82 million. The disclosure cites weak orders, delays in bringing new equipment into operation and weak utilization at Nippon Shikizai France. - 2026-04-13WorsenedEarnings
「In addition to lower revenue and soaring personnel expenses and general prices, delays in the operation of some new equipment at THEPENIER and sluggish operations at Nippon Shikizai France resulted in an operating loss of ¥82 million, compared with an operating loss of ¥73 million in the previous consolidated fiscal year.」
The European segment's operating loss widened, with weak orders, delays in starting new equipment and sluggish subsidiary operations cited. - FY2026-H1WorsenedAnnual report
「Orders for pharmaceuticals and cosmetics remained weak, and revenue declined both in euro terms and after conversion into yen, falling 11.8% year on year to ¥2,338 million. Profit was affected by the revenue decline and higher personnel and other costs, as well as delays in bringing some new equipment at THEPENIER into operation and weak utilization at Nippon Shikizai France, resulting in an operating loss of ¥83 million, compared with an operating loss of ¥13 million in the same period of the previous year.」
The European business's revenue decline and operating loss widened as weak orders for pharmaceuticals and cosmetics coincided with delays in bringing new equipment into operation and weak utilization at Nippon Shikizai France. - FY2025-H1WorsenedAnnual report
「Orders for pharmaceuticals and cosmetics slowed, reducing euro-denominated revenue, but yen-denominated revenue rose 4.9% year on year to ¥2,652 million due to the weaker yen. Profit was affected by lower euro-denominated revenue and higher personnel and other costs, resulting in an operating loss of ¥13 million, compared with operating profit of ¥240 million in the same period of the previous year.」
Although yen-denominated revenue increased due to the weaker yen, the French business deteriorated from operating profit in the same period of the previous year to an operating loss due to lower euro-denominated revenue and higher costs. - FY2025-Q1WorsenedAnnual report
「Profit was affected by lower euro-denominated revenue and higher personnel and other costs, resulting in an operating loss of ¥54 million, compared with operating profit of ¥118 million in the same period of the previous year.」
The French business deteriorated from operating profit in the same period of the previous year to an operating loss due to lower euro-denominated revenue and higher costs. - FY2024-Q3AdvancedAnnual report
「In Europe, where the subsidiaries THEPENIER PHARMA & COSMETICS S.A.S. and Nippon Shikizai France S.A.S. are located, orders for pharmaceuticals and cosmetics increased as the impact of COVID-19 eased significantly during the nine-month cumulative consolidated period under review (January–September), and revenue rose 71.6% year on year to ¥3,689 million. Profit benefited from the substantial revenue increase, particularly the increase in pharmaceutical orders, which improved the utilization of equipment invested in recent years. This offset higher expenses associated with capital investment and surging energy and other prices resulting from Russia's invasion of Ukraine, lifting operating profit 493.7% year on year to ¥178 million.」
The French business's revenue rose 71.6% year on year and operating profit rose 493.7% on increased pharmaceutical and cosmetics orders and improved equipment utilization. - FY2024-Q2AdvancedAnnual report
「Orders for pharmaceuticals and cosmetics increased, and revenue rose 85.8% year on year to ¥2,529 million. Profit benefited from the substantial revenue increase, particularly the increase in pharmaceutical orders, which improved the utilization of equipment invested in recent years. Operating profit therefore improved substantially year on year to ¥240 million, compared with an operating loss of ¥27 million in the same period of the previous year.」
The French business posted substantial revenue growth and returned from an operating loss to operating profit on increased orders and improved equipment utilization. - FY2024-Q1AdvancedAnnual report
「Europe, where the subsidiaries THEPENIER PHARMA & COSMETICS S.A.S. and Nippon Shikizai France S.A.S. are located, continued to be affected by Russia's invasion of Ukraine during the first-quarter cumulative consolidated period under review (January–March). However, as the impact of COVID-19 eased, orders for cosmetics and pharmaceuticals began to recover, and revenue rose 105.5% year on year to ¥1,213 million. Although profit was affected by higher expenses associated with capital investment and surging energy and other prices resulting from the invasion, the substantial revenue increase helped lift operating profit to ¥118 million, compared with an operating loss of ¥85 million in the same period of the previous year.」
The European business posted 105.5% year-on-year revenue growth and returned from an operating loss to operating profit, supported by recovering orders and the easing impact of COVID-19. - FY2023AdvancedAnnual report
「(France) France reported revenue of ¥3,155 million, up 43.3% from the previous consolidated fiscal year, and operating profit of ¥25 million, up 42.5%.」
The France segment posted higher revenue and profit, including the consolidation of Nippon Shikizai France and the recovery in orders. - FY2023-Q3AdvancedAnnual report
「Europe, where the subsidiaries THEPENIER PHARMA & COSMETICS S.A.S. (hereinafter, “THEPENIER”) and Nippon Shikizai France are located, was significantly affected by both COVID-19 and Russia's invasion of Ukraine during the nine-month cumulative consolidated period under review (January–September). However, revenue rose 44.9% year on year to ¥2,150 million, reflecting increased orders and the addition of Nippon Shikizai France to the scope of consolidation. Although profit was affected by higher expenses associated with capital investment, surging energy and other prices resulting from the invasion and logistics delays, operating profit was ¥30 million, compared with an operating loss of ¥15 million in the same period of the previous year.」
The French business posted 44.9% revenue growth on the consolidation of Nippon Shikizai France and increased orders, improving from an operating loss of ¥15 million to operating profit of ¥30 million. - FY2023-Q2AdvancedAnnual report
「Revenue was ¥1,361 million, up 33.5% year on year, reflecting increased orders at the subsidiary and the addition of Nippon Shikizai France to the scope of consolidation. Profit was affected not only by higher expenses associated with capital investment but also by surging energy and other prices and logistics delays resulting from Russia's invasion of Ukraine, resulting in an operating loss of ¥27 million, compared with an operating loss of ¥31 million in the same period of the previous year.」
The French business posted higher revenue partly due to the consolidation of Nippon Shikizai France and other factors, while its operating loss narrowed from ¥31 million in the same period of the previous year to ¥27 million, although it remained in the red. - FY2023-Q1WorsenedAnnual report
「Profit was affected not only by higher expenses associated with capital investment but also by surging energy and other prices and logistics delays resulting from Russia's invasion of Ukraine, resulting in an operating loss of ¥85 million, compared with an operating loss of ¥59 million in the same period of the previous year.」
Although revenue increased partly due to the consolidation of Nippon Shikizai France, the French business's operating loss widened from ¥59 million in the same period of the previous year to ¥85 million. - FY2022Full-year operating profit, but substantially lower profitAnnual report
「(France) France reported revenue of ¥2,201 million, down 7.2% from the previous consolidated fiscal year, and operating profit of ¥17 million, down 85.7%.」
The French business returned from an operating loss for the nine-month cumulative period to operating profit of ¥17 million for the full year, but revenue and profit declined substantially from the previous fiscal year. - FY2022-Q3WorsenedAnnual report
「THEPENIER's revenue also fell substantially to ¥1,483 million, down 19.5% from the same period of the previous year, including the previous year's first quarter, January–March 2020, which was largely unaffected by COVID-19. Profit was also affected by higher expenses associated with capital investment in addition to the substantial revenue decline, resulting in an operating loss of ¥15 million, compared with operating profit of ¥149 million in the same period of the previous year.」
THEPENIER posted a substantial revenue decline, with operating performance deteriorating from operating profit of ¥149 million in the same period of the previous year to an operating loss of ¥15 million. - FY2022-Q2WorsenedAnnual report
「THEPENIER's revenue also fell substantially to ¥1,019 million, down 26.0% from the same period of the previous year, including the previous year's first quarter, January–March 2020, which was largely unaffected by COVID-19. Profit was also affected by higher expenses associated with capital investment in addition to the substantial revenue decline, resulting in an operating loss of ¥31 million, compared with operating profit of ¥145 million in the same period of the previous year.」
THEPENIER's revenue fell 26.0% year on year for the six-month cumulative period, with operating performance deteriorating from operating profit to an operating loss. - FY2022-Q1WorsenedAnnual report
「THEPENIER's revenue also declined during the first-quarter cumulative consolidated period under review due to the impact of COVID-19」
THEPENIER reported revenue of ¥476 million, down 33.4% year on year, while operating performance deteriorated from profit in the same period of the previous year to an operating loss of ¥59 million. - FY2021Revenue was roughly flat, but profit declinedAnnual report
「France reported revenue of ¥2,372 million, down 0.4% from the previous consolidated fiscal year, and operating profit of ¥123 million, down 11.7%.」
The French business, centered on THEPENIER, kept revenue roughly flat, while operating profit declined 11.7% from the previous fiscal year. - FY2021-Q3AdvancedAnnual report
「THEPENIER was also forced to temporarily suspend operations on its cosmetics production line for a period, but reflecting strong orders and production, revenue was ¥1,844 million, up 8.0% year on year, and operating profit was ¥149 million, up 68.8%.」
Despite a temporary production shutdown, THEPENIER posted higher revenue and profit for the nine-month cumulative period, with revenue of ¥1,844 million and operating profit of ¥149 million. - FY2021-Q2AdvancedAnnual report
「THEPENIER was also forced to temporarily suspend operations on its cosmetics production line from 23 March, resuming operations on 16 April. However, reflecting strong orders and production until then, revenue was ¥1,377 million, up 16.3% year on year, and operating profit was ¥145 million, up 115.6%.」
THEPENIER posted higher revenue and profit for the first-half cumulative period, supported by strong orders even after the temporary suspension of the cosmetics production line. - FY2021-Q1Revenue and profit increased despite a temporary production shutdownAnnual report
「THEPENIER was also forced to temporarily suspend operations on its cosmetics production line from 23 March, resuming operations on 16 April. However, reflecting strong orders and production until then, revenue was ¥715 million, up 5.3% year on year, and operating profit was ¥73 million, up 77.1%.」
Although the cosmetics production line was temporarily suspended due to the spread of COVID-19, the French business posted higher revenue and profit, reflecting strong orders and production. - FY2020Full-year revenue increased, but profit declined substantially due to costs of complying with new regulationsAnnual report
「Against this business backdrop, sales of both pharmaceuticals and cosmetics grew steadily at THEPENIER, and revenue was ¥2,382 million, up 7.8% year on year. However, operating profit fell 45.1% to ¥140 million, partly because costs related to compliance with new pharmaceutical regulations increased.」
THEPENIER's pharmaceutical and cosmetics sales increased for the full year, but operating profit declined substantially due to costs related to compliance with new regulations and other factors. - FY2020-Q3Revenue increased, but profit declined due to costs of complying with new regulationsAnnual report
「Against this business backdrop, sales of both pharmaceuticals and cosmetics grew steadily at THEPENIER, and revenue was ¥1,707 million, up 13.1% year on year. However, operating profit fell 17.0% to ¥88 million, partly because costs related to compliance with new pharmaceutical regulations increased.」
THEPENIER's pharmaceutical and cosmetics sales increased, but operating profit fell 17.0% year on year due to higher costs, including those related to compliance with new pharmaceutical regulations. - FY2020-Q2AdvancedAnnual report
「Against this business backdrop, sales of both pharmaceuticals and cosmetics grew steadily at THEPENIER, resulting in higher revenue and profit year on year both on a local-currency basis and after conversion into yen. Revenue was ¥1,184 million, up 28.9% year on year, and operating profit was ¥67 million, up 53.9%.」
THEPENIER posted revenue of ¥1,184 million and operating profit of ¥67 million for the six-month cumulative period on growth in pharmaceuticals and cosmetics, resulting in higher revenue and profit year on year. - FY2020-Q1AdvancedAnnual report
「Against this business backdrop, sales of both pharmaceuticals and cosmetics grew steadily at THEPENIER, resulting in higher revenue and profit year on year both on a local-currency basis and after conversion into yen. Revenue was ¥679 million, up 56.1% year on year, and operating profit was ¥41 million, up 417.2%.」
THEPENIER posted substantial increases in revenue and profit year on year as pharmaceutical and cosmetics sales grew, with revenue of ¥679 million and operating profit of ¥41 million. - FY2019-Q3AdvancedAnnual report
「Against this business backdrop, THEPENIER recorded sales steadily, posting higher revenue and profit year on year both on a local-currency basis and after conversion into yen. Revenue was ¥1,509 million, up 19.3% year on year, and operating profit was ¥106 million, up 166.0%.」
THEPENIER posted higher revenue and profit for the nine-month cumulative period, with revenue of ¥1,509 million and operating profit of ¥106 million. - FY2019-Q2WorsenedAnnual report
「At THEPENIER, revenue and profit both declined from the same period of the previous year on a local-currency basis because some sales to major customers were delayed. However, yen-denominated revenue rose 0.7% year on year to ¥919 million due to foreign-exchange effects, while operating profit fell 47.9% to ¥43 million.」
Delayed sales to major customers resulted in lower revenue and profit for THEPENIER on a local-currency basis, while operating profit after conversion into yen fell 47.9% year on year to ¥43 million. - FY2019-Q1WorsenedAnnual report
「Against this business backdrop, THEPENIER's revenue and profit both declined from the same period of the previous year, mainly because sales from orders for its core pharmaceuticals were deferred until after the second quarter at the customer's request. As a result, revenue was ¥435 million, down 2.2% year on year, and operating profit was ¥7 million, down 83.9%.」
Sales of core pharmaceuticals were deferred until after the second quarter at the customer's request, resulting in lower revenue at THEPENIER and a decline in operating profit to ¥7 million, down 83.9% year on year. - FY2018Slight revenue growth, but lower operating profitAnnual report
「At THEPENIER, orders for core pharmaceuticals remained firm throughout the year, and the decline in operating capacity caused by the extended summer shutdown was offset by subsequent mass-production benefits and improved production efficiency. Revenue and profit were therefore both roughly at the previous year's levels. As a result, revenue for the fiscal year was ¥1,750 million, up 0.9% year on year, and operating profit was ¥103 million, down 10.3%.」
The decline in operating capacity was offset by orders for core pharmaceuticals, mass-production benefits and improved production efficiency, but revenue edged up while operating profit fell 10.3% year on year. - FY2018-Q3Growth slowed after the first-half rebound, and profit fell short of the planAnnual report
「Against this business backdrop, growth in THEPENIER's core pharmaceuticals, which had remained strong through the first half, slowed due to a decline following the first-half surge. Revenue therefore ended at roughly the level initially forecast, while profit was slightly below the initial forecast. As a result, revenue for the third-quarter cumulative consolidated period was ¥1,265 million, down 2.2% year on year, and operating profit was ¥40 million, down 40.9%.」
THEPENIER's core pharmaceuticals saw slower growth following the first-half surge, with revenue down 2.2% year on year and operating profit down 40.9%. - FY2018-Q2Ahead of plan but lower sales and earnings year on yearAnnual report
「Against this business backdrop, THEPENIER maintained strong performance in its core pharmaceuticals and secured revenue substantially above the initial plan. However, revenue was ¥912 million, down 5.0% from the same period of the previous year, while operating profit was ¥83 million, down 8.2%.」
Although orders for core pharmaceuticals substantially exceeded the plan, THEPENIER's revenue and operating profit declined year on year. - FY2018-Q1AdvancedAnnual report
「Against this business backdrop, THEPENIER posted substantial increases in revenue and profit on a euro basis as its core pharmaceuticals grew. As a result, revenue in France for the first-quarter cumulative consolidated period was ¥444 million, up 8.9% year on year, and operating profit was ¥49 million, up 129.7%.」
THEPENIER reported revenue of ¥444 million and operating profit of ¥49 million on growth in its core pharmaceuticals, posting higher revenue and profit year on year. - FY2017AdvancedAnnual report
「At THEPENIER, revenue and profit increased on a euro basis as its core pharmaceuticals and makeup products grew from the previous fiscal year. However, revenue declined slightly after conversion into yen due to the stronger yen and weaker euro. As a result, revenue for the fiscal year was ¥1,734 million, down 0.9% year on year, while operating profit was ¥115 million, up 87.8%.」
Revenue and profit increased on a local-currency basis on growth in core pharmaceuticals and makeup products, with operating profit rising to ¥115 million. In contrast, yen-denominated revenue declined due to the stronger yen and weaker euro. - FY2017-Q3AdvancedAnnual report
「Against this business backdrop, THEPENIER posted higher revenue and profit as sales of lotion and its core pharmaceuticals increased from the same period of the previous year. As a result, revenue for the third-quarter cumulative consolidated period was ¥1,293 million, up 7.0% year on year, and operating profit was ¥68 million, compared with an operating loss of ¥3 million in the same period of the previous year.」
THEPENIER posted higher revenue and profit on growth in lotion and core pharmaceutical sales, improving from an operating loss to operating profit of ¥68 million. - FY2017-Q2AdvancedAnnual report
「Against this business backdrop, THEPENIER posted higher revenue and profit as sales of lotion and its core pharmaceuticals increased from the same period of the previous year. As a result, revenue for the second-quarter cumulative consolidated period was ¥960 million, up 28.8% year on year, and operating profit was ¥91 million, compared with an operating loss of ¥25 million in the same period of the previous year.」
THEPENIER posted higher revenue and profit on growth in lotion and core pharmaceutical sales, improving from an operating loss to operating profit of ¥91 million. - FY2017-Q1AdvancedAnnual report
「At THEPENIER, revenue and profit increased as production of its core pharmaceuticals grew from the same period of the previous year. As a result, revenue for the first-quarter cumulative consolidated period was ¥408 million, up 5.0% year on year, and operating profit was ¥21 million, compared with an operating loss of ¥9 million in the same period of the previous year.」
THEPENIER posted higher revenue and profit on increased production of its core pharmaceuticals, improving from an operating loss to operating profit of ¥21 million. - FY2016First statedAnnual report
「Although the company had continued to underperform since its acquisition in 2000, its performance recovered through the Company’s comprehensive support and it returned to profitability during the fiscal year under review.」
The French subsidiary returned to profitability during the year following support from the Company.